Zura Bio Limited Class A Ordinary Shares ZURA
i
Market datapartial · fetched 2026-11-07T05:12:07.334Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:28:53.956103435Z
FundamentalsAlpha Vantage · unavailable
Zura Bio Limited Class A Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.88 | 405.3% | 43.7% | |||
| 25Δ | 10.00 | 426.6% | 154.3% | 3.30 | 413.4% | 39.3% |
| 30Δ | 9.38 | 448.8% | 141.7% | 3.71 | 421.5% | 34.9% |
| 35Δ | 8.70 | 466.4% | 127.7% | 4.16 | 428.2% | 30.8% |
| 40Δ | 7.91 | 477.0% | 111.2% | 4.68 | 431.7% | 27.6% |
| 45Δ | 7.08 | 479.2% | 93.8% | 5.23 | 433.5% | 24.4% |
| 50Δ | 6.21 | 472.4% | 75.3% | 5.80 | 432.8% | 21.2% |
| 55Δ | 5.11 | 415.1% | 49.3% | 6.28 | 420.3% | 18.2% |
| 60Δ | 4.50 | 386.7% | 36.3% | 6.71 | 401.6% | 15.2% |
| 65Δ | 3.96 | 364.6% | 25.5% | 7.13 | 382.8% | 12.3% |
| 70Δ | 3.61 | 359.5% | 21.0% | 7.69 | 369.9% | 9.5% |
| 75Δ | 3.26 | 354.4% | 16.5% | 9.33 | 401.7% | 7.9% |
| 80Δ | 2.90 | 349.4% | 12.0% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.88
- IV
- 405.3%
- B/E move
- 43.7%
25Δ
- Pseudo strike
- 10.00
- IV
- 426.6%
- B/E move
- 154.3%
- Pseudo strike
- 3.30
- IV
- 413.4%
- B/E move
- 39.3%
30Δ
- Pseudo strike
- 9.38
- IV
- 448.8%
- B/E move
- 141.7%
- Pseudo strike
- 3.71
- IV
- 421.5%
- B/E move
- 34.9%
35Δ
- Pseudo strike
- 8.70
- IV
- 466.4%
- B/E move
- 127.7%
- Pseudo strike
- 4.16
- IV
- 428.2%
- B/E move
- 30.8%
40Δ
- Pseudo strike
- 7.91
- IV
- 477.0%
- B/E move
- 111.2%
- Pseudo strike
- 4.68
- IV
- 431.7%
- B/E move
- 27.6%
45Δ
- Pseudo strike
- 7.08
- IV
- 479.2%
- B/E move
- 93.8%
- Pseudo strike
- 5.23
- IV
- 433.5%
- B/E move
- 24.4%
50Δ
- Pseudo strike
- 6.21
- IV
- 472.4%
- B/E move
- 75.3%
- Pseudo strike
- 5.80
- IV
- 432.8%
- B/E move
- 21.2%
55Δ
- Pseudo strike
- 5.11
- IV
- 415.1%
- B/E move
- 49.3%
- Pseudo strike
- 6.28
- IV
- 420.3%
- B/E move
- 18.2%
60Δ
- Pseudo strike
- 4.50
- IV
- 386.7%
- B/E move
- 36.3%
- Pseudo strike
- 6.71
- IV
- 401.6%
- B/E move
- 15.2%
65Δ
- Pseudo strike
- 3.96
- IV
- 364.6%
- B/E move
- 25.5%
- Pseudo strike
- 7.13
- IV
- 382.8%
- B/E move
- 12.3%
70Δ
- Pseudo strike
- 3.61
- IV
- 359.5%
- B/E move
- 21.0%
- Pseudo strike
- 7.69
- IV
- 369.9%
- B/E move
- 9.5%
75Δ
- Pseudo strike
- 3.26
- IV
- 354.4%
- B/E move
- 16.5%
- Pseudo strike
- 9.33
- IV
- 401.7%
- B/E move
- 7.9%
80Δ
- Pseudo strike
- 2.90
- IV
- 349.4%
- B/E move
- 12.0%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 236.13% | |
| 257.90% |
Biotechnology
ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The…
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
More →ABEO
Description unavailable
More →ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative…
More →